GlassScriptPhysician profile
Randall N Beyl
NPI 1356630958
$112,416.38
in general payments reported to CMS, 2019-2025
35 companies · $7,996 in 2025
The $7,996 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $15K · 2021: $19K · 2022: $24K · 2023: $19K · 2024: $12K · 2025: $7,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $7,988 · Consulting Fee: $6,355 · Travel and Lodging: $2,350 · Education: $21.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,437.50 |
| Food and Beverage | $7,988.25 |
| Consulting Fee | $6,355.00 |
| Travel and Lodging | $2,350.37 |
| Education | $21.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $64,179.33 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Lilly USA, LLC | $24,722.22 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $7,879.56 | 2019-2025 | |
| Janssen Biotech, INC. | $6,220.86 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Glaxosmithkline, LLC. | $2,636.01 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $1,322.66 | 2021-2025 | Saphnelo |
| Pfizer INC. | $1,024.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,008.21 | 2019-2025 | Orencia |
| Amgen INC. | $863.23 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $360.31 | 2020-2025 | Cimzia, Bimzelx |
| Janssen Scientific Affairs, LLC | $248.63 | 2019-2023 | Tremfya |
| Alexion Pharmaceuticals, INC. | $245.12 | 2019-2024 | Strensiq |
| Mallinckrodt Hospital Products INC. | $228.83 | 2020-2024 | Acthar |
| Radius Health, INC. | $202.41 | 2019-2025 | Tymlos |
| Regeneron Healthcare Solutions, INC. | $196.96 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $156.64 | 2019-2025 | Actemra, Gazyva |
| Ani Pharmaceuticals, INC. | $127.53 | 2023-2025 | Purified Cortrophin Gel |
| Celgene Corporation | $114.61 | 2019 | |
| Aurinia Pharma U.S., INC. | $94.39 | 2022-2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $87.46 | 2023-2024 | Idacio |
| Organon LLC | $64.33 | 2023-2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.87 | 2023-2025 | Cyltezo |
| Genzyme Corporation | $54.47 | 2025 | |
| Scilex Pharmaceuticals INC. | $52.48 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $52.17 | 2023-2024 | Zilretta, Iovera, Exparel |
| Mallinckrodt Enterprises LLC | $44.91 | 2019 | |
| Bioventus LLC | $43.82 | 2019 | |
| Celltrion USA INC. | $21.63 | 2023 | Yuflyma |
| Sobi, INC | $18.33 | 2022 | |
| Alvogen INC | $17.82 | 2025 | Teriparatide |
| Depuy Synthes Sales INC. | $15.09 | 2024 | Orthovisc |
| Kyowa Kirin, INC. | $14.71 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $14.24 | 2022 | |
| Antares Pharma, INC. | $11.48 | 2020 | |
| Avion Pharmaceuticals | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Beyl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.